Physician profile
David Koh
NPI 1447710637
$1,639.65
in general payments reported to CMS, 2019-2025
13 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.94 · 2024: $1,113 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.87 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $284.80 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $275.88 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $234.11 | 2024-2025 | |
| Lilly USA, LLC | $164.73 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $149.96 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $57.73 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Dynavax Technologies Corporation | $55.86 | 2024 | Heplisav-B |
| Astellas Pharma US INC | $18.50 | 2024 | Veozah |
| Sanofi Pasteur INC. | $18.23 | 2025 | |
| Amgen INC. | $17.42 | 2024 | Repatha, Otezla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.94 | 2019 | |
| Sumitomo Pharma America, INC. | $16.62 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Koh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.